Retatrutide (LY3437943) is a groundbreaking triple hormone receptor agonist that simultaneously activates three key metabolic pathways: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.
Mechanism of Action:
Unlike single or dual agonists, Retatrutide’s triple receptor activation creates synergistic effects. GLP-1 activation enhances insulin secretion and promotes satiety. GIP receptor stimulation amplifies these metabolic benefits. Glucagon receptor activation increases energy expenditure and hepatic lipid oxidation.
Technical Specifications:
• CAS Number: 2381089-83-2
• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight: 4731.33 g/mol
• Purity: >98% (HPLC verified)
• Form: Lyophilized powder
• Storage: 2-8°C, protect from light
Research Applications:
Phase 2 clinical trials demonstrated up to 24% weight reduction over 48 weeks, making this compound of significant interest for obesity, metabolic syndrome, and NAFLD research.
For research purposes only. Not for human consumption.